Back to search

Peptide record

TPDB10984

Ranatuerin-2PLx Antibacterial Anticancer Antifungal Hemolysis Toxicity standard
28 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB10984
Ranatuerin-2PLx
Antibacterial Anticancer Antifungal Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia CancerPPD 2.0 dbACP CAFPdb PD_Hemolysis ToxinPred 3.0
standard
No
A 28-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
GIMDTVKNAAKNLAGQLLDKLKCKITAC
Physicochemical Analysis
C127H226N36O38S3
REHFPSWY
K
2961.59
9.65
5
2
12
+3
4.95
0.118
108.21
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
125
4.22
7
Residue Composition
number
4
A
0
R
2
N
2
D
2
C
0
E
1
Q
2
G
0
H
2
I
4
L
5
K
1
M
0
F
0
P
0
S
2
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 4 R: 0 N: 2 D: 2 C: 2 E: 0 Q: 1 G: 2 H: 0 I: 2 L: 4 K: 5 M: 1 F: 0 P: 0 S: 0 T: 2 W: 0 Y: 0 V: 1
Chemical Descriptors
28
C127H226N36O38S3
2961.59
9.65
+3
4.95
0.118
Free
L
Linear
Free
Antimicrobial
Rana palustris
Evidence Records 13 records
Evidence 1 Activity

Activity

IC50
IC50 = 5.90 µM
Anticancer
5.90 µM

Target

Lung Cancer
H-157
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 15.44 µM
Anticancer
15.44 µM

Target

Skin Cancer
MDA-MB-435S
Skin

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 3 Activity

Activity

IC50
IC50 = 5.79 µM
Anticancer
5.79 µM

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 4 Activity

Activity

IC50
IC50 = 16.14 µM
Anticancer
16.14 µM

Target

Brain Tumor
U-251-MG
Brain

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 5 Activity

Activity

IC50
IC50 = 20.19 µM
Anticancer
20.19 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 6 Activity

Activity

Hemolysis
Horse erythrocytes: Moderate haemolytic activity

Target

Horse erythrocytes

Source & Reference

Hemolytik PD_Hemolysis
DRAMP4
Biosci Rep. 2018 Nov 9 38(6):BSR20180710.

Other

Source Activity Label Source Definition
Hemolysis
Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 7 Activity

Activity

IC50
Toxicity
79.50 µM
Cytotoxic
IC50 | 79.50 | µM | target cell: Human microvascular endothelial cells HMEC-1

Target

Human microvascular endothelial cells HMEC-1

Source & Reference

NA
DBAASP
A novel antimicrobial peptide, Ranatuerin-2PLx, showing therapeutic potential in inhibiting proliferation of cancer cells | Biosci Rep | 2018
Evidence 8 Activity

Activity

43% hemolysis
Toxicity
512 µM
Hemolytic Cytotoxic
43% hemolysis | 512 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
A novel antimicrobial peptide, Ranatuerin-2PLx, showing therapeutic potential in inhibiting proliferation of cancer cells | Biosci Rep | 2018
Evidence 9 Activity

Activity

13% hemolysis
Toxicity
32 µM
Hemolytic Cytotoxic
13% hemolysis | 32 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
A novel antimicrobial peptide, Ranatuerin-2PLx, showing therapeutic potential in inhibiting proliferation of cancer cells | Biosci Rep | 2018
Evidence 10 Activity

Activity

<5% hemolysis
Toxicity
8 µM
Hemolytic Cytotoxic
<5% hemolysis | 8 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
A novel antimicrobial peptide, Ranatuerin-2PLx, showing therapeutic potential in inhibiting proliferation of cancer cells | Biosci Rep | 2018
Evidence 11 Activity

Activity

% Hemolysis
Toxicity
0 %
Hemolytic
Hemolytic_activity: [Ref.30279210] 0% hemolysis at 4 µM , 1% hemolysis at 8 µM , 5% hemolysis at 16 µM , 10% hemolysis at 32 µM , 13% hemolysis at 64 µM , 20% hemolysis at 128 µM , 30% hemolysis at 256 µM , 44% hemolysis at 512 µM against human red blood cells

Target

erythrocytes

Source & Reference

NA
DRAMP
Biosci Rep. 2018 Nov 9 38(6). pii: BSR20180710. doi: 10.1042/BSR20180710.
Evidence 12 Activity

Activity

IC50
Toxicity
79.50 µM
Hemolytic Cytotoxic
Hemolytic_activity: Horse erythrocytes: Moderate haemolytic activity | Cytotoxicity: HMEC-1: IC50=79.50 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Biosci Rep. 2018 Nov 9 38(6):BSR20180710.
Evidence 13 Hemolysis

Activity

Horse erythrocytes: Moderate haemolytic activity
Hemolysis

Target

Horse erythrocytes

Source & Reference

PD_Hemolysis
Biosci Rep. 2018 Nov 9 38(6):BSR20180710.
DRAMP4
PD_Hemolysis